Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q1 EPS by 174c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q1 EPS of ($1.75), $1.74 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $88.64 million versus the consensus estimate of $95.87 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• Qualcomm unveils Dragonfly CPU, signs Meta as first data center customer
• MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c